Month: June 2022

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Written by Customer Service on June 30, 2022. Posted in Public Companies.

Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone paymentsNEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based milestones. Gavreto, marketed by Roche in certain markets outside the United States and Greater China, is a once-daily rearranged during transfection (RET) targeted therapy approved in Europe in November 2021 for the treatment of certain RET-altered non-small cell lung cancers (NSCLC). Additionally, Gavreto has been submitted for marketing...

Colliers to invest in leading alternative investment manager

Written by Customer Service on June 30, 2022. Posted in Mergers And Acquisitions.

Versus adds perpetual funds and strong private wealth distribution capabilities TORONTO AND DENVER, June 30, 2022 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), announced today it has entered into a definitive agreement to acquire a significant equity interest in Versus Capital (“Versus”), a leading U.S. alternative real asset management firm with approximately $6.0 billion of assets under management. The transaction is subject to customary closing conditions and approvals and is expected to close in the fourth quarter of 2022. Financial terms of the transaction were not disclosed. Founded in 2010 and based in Denver, Versus offers alternative real asset investment solutions through actively managed, perpetual-life funds that have consistently produced...

The Simply Good Foods Company Reports Fiscal Third Quarter 2022 Financial Results

Written by Customer Service on June 30, 2022. Posted in Earnings Releases And Operating Results.

DENVER, June 30, 2022 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen and thirty-nine weeks ended May 28, 2022. Third Quarter Highlights:(1)Net sales increased 11.5% Net income(2) of $38.8 million versus $5.9 million Earnings per diluted share (“EPS”)(2) of $0.38 versus $0.06 Adjusted Diluted EPS(3) of $0.44 versus $0.43 Adjusted EBITDA(4) $63.3 million versus $67.5 million Full fiscal year 2022 outlook:Net sales expected to increase 14-15%, the Company’s previous outlook was for net sales growth of 13-15% Adjusted EBITDA(4,6) expected to increase slightly less than the net sales growth rate Adjusted Diluted EPS(3,6) expected to...

Constellation Brands Reports First Quarter Fiscal 2023 Financial Results

Written by Customer Service on June 30, 2022. Posted in Earnings Releases And Operating Results.

VICTOR, N.Y., June 30, 2022 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, reported today its first quarter fiscal 2023 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Thursday, June 30, 2022 at 10:30 a.m. EDT. Visit ir.cbrands.com to locate information for joining the conference call or a live, listen-only webcast of the conference call. ABOUT CONSTELLATION BRANDSAt Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

Written by Customer Service on June 30, 2022. Posted in Earnings Releases And Operating Results.

LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended March 31, 2022. Recent Highlights (including post period events)Successful completion of $30.0 million financing package ($26.8 million gross proceeds) Multiple data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions® meeting Focused on the value of KidneyIntelX testing in patients with type 2 diabetes (T2D) and early-stage chronic kidney disease (CKD):KidneyIntelX ability to assess risk of heart failure hospitalization and death in large international...

Venus Concept to Release Second Quarter of Fiscal Year 2022 Financial Results on August 12, 2022

Written by Customer Service on June 30, 2022. Posted in Public Companies.

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2022 financial results will be released before the market opens on Friday, August 12, 2022. Management will host a conference call at 8:00 a.m. Eastern Time on August 12, 2022 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13731063. A live webcast of the call will also be provided on the investor relations section of the Company’s website at ir.venusconcept.com. For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415...

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

Written by Customer Service on June 30, 2022. Posted in Public Companies.

First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease (cLDD). The clinical study is being conducted at up to 15 sites in the United States. “Announcing first patient enrollment is our most significant clinical milestone to date and an exciting milestone for BioRestorative’s clinical programs overall,” said Lance Alstodt, CEO of BioRestorative Therapies. “The initiation of patient enrollment in...

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022

Written by Customer Service on June 30, 2022. Posted in Public Companies.

CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, August 9th. Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived...

MariMed Announces the Filing of its final Non-Offering Prospectus

Written by Customer Service on June 30, 2022. Posted in Public Companies.

Sets Stage For Dual Listing on the Canadian Securities Exchange NORWOOD, Mass., June 30, 2022 (GLOBE NEWSWIRE) — MariMed, Inc. (“MariMed” or the “Company”) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has obtained a receipt for its final non-offering, long form prospectus dated June 29, 2022 from the Ontario Securities Commission. Concurrent with its prospectus filing, the Company also received conditional approval from the Canadian Securities Exchange (the “CSE”) to list the Company’s common shares on the CSE under the symbol “MRMD”. Listing of the common shares is subject to the satisfaction of certain customary conditions, including the receipt by the CSE of all final documentation. The Company anticipates the dual listing on the CSE to be effective...

CORRECTING AND REPLACING: AgEagle Aerial Systems Announces Pricing of $10 Million Registered Direct Offering

Written by Customer Service on June 30, 2022. Posted in Public Companies.

WICHITA, Kan., June 30, 2022 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE American: UAVS) (“AgEagle” or the “Company”), an industry-leading provider of full-stack drone, sensor and software solutions for commercial and government/defense use, today announced that, it has entered into a securities purchase agreement with an institutional investment firm (the “Investor”), which is an existing AgEagle shareholder. Pursuant to the agreement, the Investor will purchase 10,000 shares of Series F 5% Convertible Preferred Stock (the “Series F Convertible Preferred”) and warrants to purchase up to 16,129,032 shares of common stock at an exercise price of $0.96 per share (the “Warrants”), for gross proceeds of approximately $10 million. The Series F Convertible Preferred will be convertible into 16,129,032 shares of the Company’s...

Month: June 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice